ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis

被引:191
作者
Finkielman, Javier D.
Lee, Augustine S.
Hummel, Amber M.
Viss, Margaret A.
Jacob, Gregory L.
Homburger, Henry A.
Peikert, Tobias
Hoffman, Gary S.
Merkel, Peter A.
Spiera, Robert
St. Clair, E. William
Davis, John C., Jr.
McCune, W. Joseph
Tibbs, Andrea K.
Ytterberg, Steven R.
Stone, John H.
Specks, Ulrich [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Div Pulm & Crit Care Med, Thorac Dis Res Unit, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Div Clin Biochem & Immunol, Antibody Immunol Lab, Rochester, MN USA
[3] Cleveland Clin Fdn, Ctr Vasc Res & Care, Cleveland, OH USA
[4] Boston Univ, Boston, MA 02215 USA
[5] Univ Michigan, Ann Arbor, MI 48109 USA
[6] Johns Hopkins Univ, Ctr Clin Trials, Baltimore, MD USA
[7] Mayo Clin, Rochester, MN USA
[8] Johns Hopkins Univ, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
antineutrophil cytoplasmic antibodies; enzyme-linked immunosorbent assay; fluorescent antibody technique; Wegener's granulomatosis;
D O I
10.1016/j.amjmed.2006.08.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The pathogenic significance of antineutrophilic cytoplasmic antibodies (ANCA) in Wegener's granulomatosis is controversial. Their presence is influenced by the extent, severity, and activity of the disease at the time of sampling. The objective of this study was to determine the frequency of ANCA in patients with active Wegener's granulomatosis and to assess the influence of disease severity on test results. METHODS: Baseline serum samples from the 180 participants in a multicentric prospective trial were tested for ANCA by indirect immunofluorescence, direct enzyme-linked immunosorbent assay (ELISA), and capture ELISA. Disease activity was measured using the Birmingham Vasculitis Activity Score for Wegener's granulomatosis. All patients had active disease at enrollment. Patients were categorized as having severe (n = 128) or limited (n = 52) Wegener's granulomatosis. RESULTS: When all ANCA detection methods were combined, 166 patients (92%) were ANCA positive, including 96% with severe disease and 83% with limited disease. CONCLUSION: ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis, but approximately 1 of 5 patients with active limited disease are ANCA negative. Immunofluorescence and both direct and capture ELISAs are required for optimal detection, suggesting that ANCA are not recognized equally well by all testing methods. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:643.e9 / 643.e14
页数:6
相关论文
共 22 条
  • [11] THE ROLE OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (C-ANCA) TESTING IN THE DIAGNOSIS OF WEGENER GRANULOMATOSIS - A LITERATURE-REVIEW AND METAANALYSIS
    RAO, JK
    WEINBERGER, M
    ODDONE, EZ
    ALLEN, NB
    LANDSMAN, P
    FEUSSNER, JR
    [J]. ANNALS OF INTERNAL MEDICINE, 1995, 123 (12) : 925 - +
  • [12] Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions
    Russell, KA
    Wiegert, E
    Schroeder, DR
    Homburger, HA
    Specks, U
    [J]. CLINICAL IMMUNOLOGY, 2002, 103 (02) : 196 - 203
  • [13] Antineutrophil cytoplasmic antibodies and associated diseases: A review of the clinical and laboratory features
    Savige, J
    Davies, D
    Falk, RJ
    Jennette, JC
    Wiik, A
    [J]. KIDNEY INTERNATIONAL, 2000, 57 (03) : 846 - 862
  • [14] Specks U, 2004, CLIN EXP RHEUMATOL, V22, pS7
  • [15] Stone JH, 2005, NEW ENGL J MED, V352, P351
  • [16] Validation of a computer version of the American College of Rheumatology Patient Assessment questionnaire for the autonomous self-entry of self-report data in an urban rheumatology clinic - Reply
    Stone, JH
    Holbrook, JT
    Tibbs, A
    Hoffman, GS
    Allen, NB
    St Clair, EW
    Davis, JC
    Merkel, PA
    Specks, U
    Spiera, RF
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (01): : 335 - 336
  • [17] Stone JH, 2002, CONTROL CLIN TRIALS, V23, P450
  • [18] Stone JH, 2001, ARTHRITIS RHEUM, V44, P912, DOI 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.3.CO
  • [19] 2-X
  • [20] Sun J, 1998, CLIN EXP IMMUNOL, V114, P320